We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS Clinical Trials Groups 209 and 214.
- Authors
Schooley, R T; Spino, C; Kuritzkes, D; Walker, B D; Valentine, F A; Hirsch, M S; Cooney, E; Friedland, G; Kundu, S; Merigan, T C, Jr; McElrath, M J; Collier, A; Plaeger, S; Mitsuyasu, R; Kahn, J; Haslett, P; Uherova, P; deGruttola, V; Chiu, S; Zhang, B; Jones, G; Bell, D; Ketter, N; Twadell, T; Chernoff, D; Rosandich, M
- Abstract
The potential role of human immunodeficiency virus type 1 (HIV-1)-specific immune responses in controlling viral replication in vivo has stimulated interest in enhancing virus-specific immunity by vaccinating infected individuals with HIV-1 or its components. These studies were undertaken to define patient populations most likely to respond to vaccination, with the induction of novel HIV-1-specific cellular immune responses, and to compare the safety and immunogenicity of several candidate recombinant HIV-1 envelope vaccines and adjuvants. New lymphoproliferative responses (LPRs) developed in <30% of vaccine recipients. LPRs were elicited primarily in study participants with a CD4 cell count >350 cells/mm(3) and were usually strain restricted. Responders tended to be more likely than nonresponders to have an undetectable level of HIV-1 RNA at baseline (P=.067). Induction of new cellular immune responses by HIV-1 envelope vaccines is a function of the immunologic stage of disease and baseline plasma HIV-1 RNA level and exhibits considerable vaccine strain specificity.
- Publication
The Journal of infectious diseases, 2000, Vol 182, Issue 5, p1357
- ISSN
0022-1899
- Publication type
Journal Article
- DOI
10.1086/315860